Myocardial protection and ischemia tolerance of the globally ischemic heart. 1990

M M Gebhard
Physiology and Pathophysiology Center, University of Göttingen, FRG.

The pathophysiological fundamentals of the tolerance of the heart to the ischemic condition are discussed, with special reference to three contributions in Issue 1/1990 of this journal. The relationship 'duration of/damage done by' ischemia is of sigmoidal form. The time needed to recover from the damage caused is dependent on the extent of the damage and not on the duration of ischemia. This time is thus a measure of the damage caused. The two main means of reducing this damage are cardioplegia and hypothermia. The fundamental differences in the various cardioplegic methods, and the factors on which their effectiveness depends, are explained. The background to the use of hypothermia and the limits in its application are presented. The dependence on hypothermia to extend the useful duration of ischemia demands, however, a careful consideration of the physiological thermodynamics involved, when estimating the probable extent of damage reached at any time.

UI MeSH Term Description Entries
D007036 Hypothermia, Induced Abnormally low BODY TEMPERATURE that is intentionally induced in warm-blooded animals by artificial means. In humans, mild or moderate hypothermia has been used to reduce tissue damages, particularly after cardiac or spinal cord injuries and during subsequent surgeries. Induced Hypothermia,Mild Hypothermia, Induced,Moderate Hypothermia, Induced,Targeted Temperature Management,Therapeutic Hypothermia,Hypothermia, Therapeutic,Induced Mild Hypothermia,Induced Mild Hypothermias,Induced Moderate Hypothermia,Induced Moderate Hypothermias,Mild Hypothermias, Induced,Moderate Hypothermias, Induced,Targeted Temperature Managements
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D002314 Cardioplegic Solutions Solutions which, upon administration, will temporarily arrest cardiac activity. They are used in the performance of heart surgery. Cardioplegic Solution,Solution, Cardioplegic,Solutions, Cardioplegic
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D006324 Heart Arrest, Induced A procedure to stop the contraction of MYOCARDIUM during HEART SURGERY. It is usually achieved with the use of chemicals (CARDIOPLEGIC SOLUTIONS) or cold temperature (such as chilled perfusate). Cardiac Arrest, Induced,Cardioplegia,Induced Cardiac Arrest,Induced Heart Arrest,Cardioplegias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2

Related Publications

M M Gebhard
January 1990, Journal of molecular and cellular cardiology,
M M Gebhard
October 1982, Revista clinica espanola,
M M Gebhard
April 1979, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
M M Gebhard
January 1988, Vutreshni bolesti,
M M Gebhard
February 1978, Arquivos brasileiros de cardiologia,
M M Gebhard
January 2001, Advances in experimental medicine and biology,
M M Gebhard
September 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
M M Gebhard
April 1987, The Canadian journal of cardiology,
Copied contents to your clipboard!